Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT05630001
- Locations
- 🇺🇸
City Of Hope National Med Center, Duarte, California, United States
🇺🇸Lakes Research, Miami Lakes, Florida, United States
🇺🇸Huntsman Cancer Institute Univ of Utah, Salt Lake City, Utah, United States
The 'Wearing Off' Effect of DMT
- Conditions
- Interventions
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 39
- Registration Number
- NCT05627271
- Locations
- 🇨🇭
Novartis Investigative Site, Basel, Switzerland
Regulatory Post-Marketing Surveillance of Xolair® for Chronic Rhinosinusitis With Nasal Polyps
- First Posted Date
- 2022-11-23
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 112
- Registration Number
- NCT05626257
- Locations
- 🇰🇷
Novartis Investigative Site, Bundang Gu, Gyeonggi Do, Korea, Republic of
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 280
- Registration Number
- NCT05624749
- Locations
- 🇺🇸
Pinnacle Research Group LLC, Anniston, Alabama, United States
🇺🇸University of Calif Irvine Med Cntr, Irvine, California, United States
🇺🇸Advanced Medical Research, La Palma, California, United States
A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission
- Conditions
- Interventions
- First Posted Date
- 2022-11-21
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 340
- Registration Number
- NCT05622708
- Locations
- 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam
A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea
- First Posted Date
- 2022-11-18
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 127
- Registration Number
- NCT05621733
- Locations
- 🇰🇷
Novartis Investigative Site, Taegu, Korea, Republic of
French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML Patients
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT05619978
- Locations
- 🇫🇷
Novartis Investigative Site, Lyon, France
Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9230
- Registration Number
- NCT05613140
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
Clinical Outcomes of 3L+ Therapies Among Patients With Chronic Myeloid Leukemia and Those With T315I Mutation
- Conditions
- First Posted Date
- 2022-11-09
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 164
- Registration Number
- NCT05611216
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden
- First Posted Date
- 2022-11-09
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1975
- Registration Number
- NCT05611229
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States